Published: Tue, August 29, 2017
Economy | By Melissa Porter

SunTrust Robinson Humphrey Cuts Rating On Kite Pharma, Inc. (KITE) To "Hold"

SunTrust Robinson Humphrey Cuts Rating On Kite Pharma, Inc. (KITE) To

(NASDAQ:GILD). Chilton Capital Mngmt Limited owns 0.63% invested in Gilead Sciences, Inc. About 882,321 shares traded.

Skba Capital Management LLC purchased a new stake in Gilead Sciences, Inc.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Corey Davis and John Newman have a yearly average loss of 1.2% and 2.0% respectively. California Employees Retirement System accumulated 35,227 shares. It has underperformed by 38.50% the S&P500.

Analysts have a mean recommendation of 2.50 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). Therefore 63% are positive. Kite Pharma had 45 analyst reports since August 4, 2015 according to SRatingsIntel. The company was initiated on Tuesday, September 29 by TH Capital. Should the deal fall through, Gilead will pay Kite a $356 million termination fee, Gilead said in a regulatory filing. (NASDAQ:GILD) on Wednesday, March 23 with "Outperform" rating.

Gilead stock is now a Zacks Rank #2 (Buy) and scored an "A" for Value in our Style Score system. The firm has "Outperform" rating by RBC Capital Markets given on Wednesday, November 2. The company was maintained on Wednesday, July 29 by Needham. Oppenheimer maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, February 8 to "Neutral" rating. After 8.7 months of follow-up, the ORR in the DLBCL group was 36%, which included a CR rate of 31%.

More notable recent Gilead Sciences, Inc.

Now Gilead has bet that Kite will provide a payoff of a similar magnitude. Yhb Investment Inc reported 0.6% of its portfolio in Gilead Sciences, Inc.

Officials with Gilead Sciences, Inc. and Kite Pharma, Inc. have announced today the companies have entered into an agreement that enables Gilead to acquire Kite for approximately $11.9 billion, or $180 in cash per share. Its up 0.21, from 0.7 in 2016Q3.

Investors eagerly awaiting news of how Gilead Sciences' (NASDAQ: GILD) plans to spend its growing mountain of cash found out on Monday that the company's plans to become a leader in cancer treatment weren't lip-service. 30 funds opened positions while 71 raised stakes. First Personal Fincl Ser stated it has 2,810 shares or 0.01% of all its holdings. Moreover, Capital Guardian Trust Com has 0.16% invested in Kite Pharma Inc (NASDAQ:KITE). (NASDAQ:GILD) or 9,943 shares. Blackrock Fund reported 49,262 shares. Reilly Fincl Ltd Llc holds 0.05% or 3,707 shares in its portfolio.

Declining issues outnumbered advancing ones on the NYSE by a 1.21-to-1 ratio; on Nasdaq, a 1.13-to-1 ratio favored advancers. Fifth Third Bank reported 172,153 shares. (NASDAQ:GILD). Clear Harbor Asset Mgmt Ltd Liability owns 22,362 shares for 0.34% of their portfolio. "But nothing that is really shaking up the markets", said Matt Lloyd, chief investment strategist at Advisors Asset Management. Pathstone Family Office Ltd Co owns 2,197 shares. The overall volume in the last trading session was 3.69 million shares. Advantus Mgmt Incorporated owns 132,497 shares or 0.25% of their USA portfolio.

Investors sentiment decreased to 1.31 in 2016 Q4. BALTIMORE DAVID sold $569,541 worth of stock or 3,700 shares. Over the last ninety days, insiders have sold 206,666 shares of company stock worth $15,223,184. The company was downgraded on Friday, August 7 by B. Riley & Co. First PREMIER Bank now owns 19,746 shares of the biopharmaceutical company's stock valued at $1,341,000 after buying an additional 8,101 shares during the period. On Thursday, February 25 the stock rating was initiated by Citigroup with "Buy".

Like this: